MolNFT v1 · #4979 · protein
L-fuculose 1-phosphate aldolase from escherichia COLI mutant DEL(27)
1E4A: “L-fuculose 1-phosphate aldolase from escherichia COLI mutant DEL(27)”. X-ray diffraction, 2 ligands (ZN, SO4), 1 pocket (best druggability 0.42). MolNFT v1 #4979 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 1E4A
- Type
- protein
- Length
- 205 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- L-fuculose 1-phosphate aldolase
- EC
- 4.1.2.17
- UniProt
- P11550
- Ligands
- ZN, SO4
- Pockets
- 1 · best druggability 0.42
Structure
x-ray diffraction · 1 distinct chain · 44% helix, 17% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| P | L-fuculose 1-phosphate aldolase (EC 4.1.2.17) | protein | 205 | 44% helix, 17% strand | P11550 |
Ligands and binding sites
- ZN · Zinc ion · metal · chains P
- SO4 · Sulfate ion · ion · 2 copies · chains P
- BME · Beta-mercaptoethanol · additive · chains P
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 72 | 0.42 | 0.80 | 18 | SO4, BME |
Modifications
Observed in the structure: 1 covalent (additive adduct).
Compared structures
- 1E4A · L-Fuculose 1-Phosphate Aldolase from Escherichia coli Mutant Del(27) · the same entry in another collection · chain P against P, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P11550
- Elsewhere: RCSB PDB 1E4A · PDBe 1E4A · UniProt P11550
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.